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Abstract
Introduction: COVID-19 immunity passports could protect the right to free movement, but critics worry 
about insufficient evidence, privacy, fraud, and discrimination. We aimed to characterize the global physi-
cian community’s opinion regarding immunity passports.
Methods: Cross-sectional, random stratified sample of physicians registered with Sermo, a global networ-
king platform open to verified and licensed physicians. The survey aimed to sample 1,000 physicians divided 
among the USA, EU and rest of the world. The survey question on immunology asked physicians to offer 
their insights into whether we know enough about COVID-19 immunity and its duration to offer immu-
nity passports at the present time. 
Results: The survey was completed by 1004 physicians (67 specialties, 40 countries, 49% frontline special-
ties) with a mean (SD) age of 49.14 (12) years. Overall, 52% answered NO, 17% were UNCERTAIN, and 
31% answered YES (P <0.05). EU physicians were more likely to say YES but even among them it did not 
exceed 35% approval. US physicians (60%) were more likely to say NO.
Conclusion: Our findings suggest a current lack of support among physicians for immunity passports. It is 
hoped that ongoing research and vaccine trials will provide further clarity. 
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INTRODUCTION
As of early January 2021, over 87 million peo-
ple have been infected by SARS-CoV-2 wor-
ldwide [1] and COVID-19 immunity pas-
sports are being actively considered by several 
countries to facilitate travel and commerce 
while mitigating viral spread [2–10]. Immu-
nity passports are envisioned as official travel 
documents which prove either vaccination or 
immunity for SARS-CoV-2.  Immunity to a 
natural viral infection typically is a sequential, 
multi-dimensional process that comprises a 
non-specific innate response (to slow the pro-
gress of virus), antibodies that specifically bind 
to the virus and cellular immunity (T-cells to 
remove virus infected cells) [11].  A robust 
adaptive response may prevent re-infection by 
the same virus and may be detected by the pre-
sence of antibodies in blood [11].
Proponents argue immunity passports will 
protect the right to free movement and avoid 
penalizing those who are immune [2, 4–6, 9, 
10]. Critics worry about insufficient eviden-
ce, privacy, passport fraud, and discrimination 
[3, 7–10]. There are also co-mingled issues of 
accuracy of antibody test results, virus muta-
tion and re-infection, as well as vaccination 
[12–18]. For example, due to cross-reactivity, 
it is not yet known if antibody tests can ac-
curately discriminate between past infections 
from SARS-CoV-2 versus infections from 
other common human coronaviruses (such 
as those that cause the common cold, Middle 
East Respiratory Syndrome or Severe Acute 
Respiratory Syndrome) [11]. Overall, CO-
VID-19 presents a multiplicity of scientific 
and ethical complexity amid a global eco-
nomy that is feeling the harsh effects of lock-
downs and social distancing. Will immunity 
passports provide rescue?
Despite the ongoing debate, relatively limited 
attention has been paid to the views of practi-
cing physicians on the risks and benefits of 
immunity passports. The aim of this report is 
to present the opinions of global physicians.
METHODS
Study design and procedure
To characterize the opinions of physicians 
on this topic, we conducted a cross-sectional, 
random, stratified sampling of verified phy-
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sicians registered with Sermo, a secure digi-
tal platform for medical crowdsourcing and 
anonymous surveys. 
Study participants and sampling
The Sermo platform is exclusive to verified 
and licensed physicians and has over 800,000 
registered physicians, of all specialties, wor-
ldwide. The survey sampled physicians over 
one week in September 2020 to get repre-
sentation from the US, Europe and the rest 
of the world. As such this was an exploratory 
study and we aimed for a target sample size of 
1000 doctors equally divided between USA, 
EU and rest of the world (RoW). 
Study instruments and measures 
This was a cross-sectional, global, survey of 
doctors across 10 topics (such as digital sur-
veillance, privacy, trust, risks) of which one 
question pertained to immunology and im-
munity passports. The instrument was refined 
after initial pilot testing in a sample of 25 
doctors and then administered by an online 
survey. All questions asked doctors to give 
their opinions based on picking one answer 
from multiple choices.  In addition, some 
quantitative and qualitative questions were 
also included.  Results of other survey topi-
cs are being reported elsewhere. The survey 
question pertaining to immunity passports 
asked: “Digital immunity passports, based on 
antibody testing, are being considered to of-
fer proof (e.g. via an app or QR code) that 
a person has developed lasting immunity to 
COVID-19 and hence can return to work 
or travel freely. In your opinion, do we know 
enough about COVID-19 immunity and it’s 
duration to offer such immunity passports at 
the present time?” Possible answers were YES, 
NO and UNCERTAIN. 
Ethical aspects
This anonymous survey was conducted fol-
lowing an online informed consent process. 
The survey results were de-linked to respon-
dents’ personal identifiable information to 
create de-identified data. This analysis does 
not include any sensitive or identifiable data 
and was deemed exempt research by Duke 
University Medical Center’s institutional re-
view board.
Data analysis
Descriptive statistics were used to examine 
physicians’ characteristics and opinions by age 
group, gender, specialty and geographic region. 
Age grouping was done as younger versus ol-
der by age 50. We also examined differences 
by gender. Physicians directly diagnosing and 
treating COVID-19 were viewed as frontli-
ne (e.g. internal medicine, ICU, ED) whereas 
the rest were categorized for non-frontline 
(even though we recognize that all physicians 
may interact with or consult on COVID-19 
patients). Chi-square and analyses of variance 
tests with p-values <0.05 were viewed as qua-
litatively different. Pairwise testing was done 
using Z-test or T-test, and chi-square were 
done without correction for small samples. 
Analysis was conducted using JMP Pro 15 
from SAS as well as Protobi. 
RESULTS
Socio-demographic characteristics 
The survey was completed by 1004 physi-
cians, across 67 specialties, from 40 countries. 
The mean (SD) age was 49.14 (12) years and 
approximately 49% were in frontline special-
ties (i.e., ICU, infectious disease, ED, hospi-
talists). 21% were female, 40% were male and 
39% chose to not report their gender. 34% 
were from the US, 37% from EU and 29% 
from rest of the world. 
Physician opinions about immunity pas-
sports
Overall opinions
Among the entire sample, with regards to the 
utility of immunity passports, 52% of doctors 
answered NO, 31% answered YES, and 17% 
were UNCERTAIN (P < 0.0001). 
Frontline status
When grouped by frontline status, there was 
no significant difference between frontline 
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(30.0% YES, 53.6% NO, 16.3% UNCER-
TAIN) versus non-frontline (31.3% YES, 
51.0% NO, 17.7% UNCERTAIN) physi-
cians (P = 0.69). 
Geographic practice region
When analyzed by major geographic region, 
physicians were still more likely to say NO 
than YES but there were regional differences 
(P = 0.01). US physicians (60.3%) were signi-
ficantly more likely to say NO versus both 
EU (47.2%) (P < 0.001) and RoW physicians 
(49.5%) (P = 0.006) (Figure 1). A slight-
ly higher percent of EU physicians (34.8%) 
said YES versus 25.9% of US physicians (P 
= 0.01) but in this regard EU did not differ 
from RoW physicians (31.1%). 
Age effects
Older doctors also differed from younger doc-
tors overall (P = 0.01). Older doctors (55.7%) 
were more likely to say NO than younger 
doctors (49.2%) (P = 0.04) and less likely to 
say YES (P = 0.003). 
Gender effects
Among those who reported their gender, 
65.2% of women said NO versus 56.5% of 
men (P = 0.037). Among EU female physi-
cians, 67% said NO which was a higher num-
ber than for males respectively (P = 0.001). 
Among US female physicians, 70% said NO 
and this number rose to 80% among US older 
female physicians. While this number was hi-
gher than the respective percentages for ma-
les, it was not statistically different. The fema-
le versus male difference was not seen among 
the RoW physicians. 
DISCUSSION
Immunity passports are being actively consi-
dered by several countries and the subject of 
considerable debate [2–10]. In that context, 
our survey provides the first global insight 
into how practicing physicians think about 
this issue. Our findings suggest a current 
lack of support among the global physician 
community for immunity passports. Even in 
the EU and Asia, where physicians and rese-
archers have been working with COVID-19 
for a longer duration than other parts of the 
world, physicians in these regions generally 
believe there is not enough evidence about 
COVID-19 antibodies to warrant immunity 
passports. 
We speculate there could be many reasons 
why physicians are skeptical. The validity of 
this possibility is supported by recent confli-
cting findings about the accuracy of antibody 
tests, the duration of COVID-19 immunity, 
and how variations in test terminology can 
impact user behavior [3, 7, 10, 16–18].  The-
se data are also consistent with cautionary 
comments from the WHO that antibody 
tests (including rapid immunodiagnostics) 
to SARS-CoV-2 need further research vali-
dation at both test accuracy and effectiveness 
levels.  Suboptimal test accuracy could result 
in false positives or false negatives, both of 
which could result in harm. Further, people 
with antibodies may wrongly assume they 
are risk free and ignore public health advice 
[11]. Another explanation for our findings is 
that  the current burden of COVID-19 ca-
ses, including the second wave hitting much 
of the world, has focused physicians more 
on managing the severe, daily problems of 
morbidity and mortality [19]. From an ethics 
perspective, vaccine development and move-
ment of people across borders are both com-
munity goods, but for a physician workforce 
faced with daily demands of patients with 
COVID-19, treatment is a real-time priority, 
and the idea of patient travel is more focused 
on sending them home from the hospital he-
althy (rather than sending them off for tra-
vel). Sporadic, global reports of viral mutation 
and patient re-infection [12–14] could con-
tribute to our results, as both mutation and 
re-infection widen the scope of need for im-
munity investigations, as well as vaccine de-
velopment. Reflecting on influenza, there are 
numerous strains, but the yearly vaccines are 
of limited scope. If this pattern emerges with 
COVID-19, there could be cohorts of those 
with ‘immunity passports’ but would these be 
‘golden’ (valuable) if there is a strain misma-
tch [3]?
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Study strengths and limitations
To our knowledge, this is the first global sur-
vey to investigate the opinions of physicians 
about immunity passports. The survey benefi-
ted from a relatively large sample drawn from 
diverse specialties and practice settings across 
40 countries. The use of Sermo, a global pla-
tform of verified and licensed physicians, al-
lowed us to recruit verified frontline and non-
frontline practicing doctors. There are also 
some limitations with our survey. These inclu-
de the relative absence of respondents from 
developing regions (e.g. Africa), sampling 
bias (e.g. people registered on a platform), re-
sponse biases (e.g. degree to which they are 
interested in topic may have influenced their 
participation) and confounding effects of va-
riables not measured. Also a cross-sectional 
survey cannot determine causality or predicti-
ve validity – indeed the risks and benefits of 
immunity passports may not be fully known 
for decades. Thus, while our findings must be 
viewed as preliminary, they may provide va-
luable insights for policy makers. 
Overall, a healthy global economy requires 
a healthy population (those cured of CO-
VID-19 and those prevented from acquiring 
it). This population will need to move across 
regions for both leisure and commerce. Even 
though physicians are not yet ready for im-
munity passports, the International Air Tran-
sport Association is moving forward with the 
idea [4] and plans pilot testing of their Travel 
Pass in late 2020. It is hoped that the ongoing 
vaccine trials, analyses of serology data from 
millions of patients worldwide, and genomic 
and molecular studies of spike protein varia-
tions will provide answers to many of the un-
solved COVID-19 immunology questions [5, 
15]. 
CONCLUSION
Our survey provides foundational insights 
into how global physicians think about CO-
VID-19 immunity passports. These findings 
call for further research to establish the ac-
curacy and effectiveness of antibody testing.   
As a growing proportion of society gets vac-
cinated, there will be renewed calls for ‘im-
Figure 1. COVID-19 immunity passports: Physician responses by geographic region (n = 1004). 
* P < 0.05
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munity passports’ based on vaccination status. 
Further research is warranted to elucidate the 
duration of immunity conferred by the va-
rious COVID-19 vaccines, whether vaccina-
ted individuals could still infect others, and 
how best to ensure that any future division of 
society by immunity status does not worsen 
existing societal inequities.
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